NURIX THERAPEUTICS, INC. Retained Earnings
NURIX THERAPEUTICS, INC. (NRIX) had Retained Earnings of -$1.18 billion as of 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-07-09
- 2026-05-31: Retained Earnings (Accumulated Deficit) -$1.18B.
- 2026-02-28: Retained Earnings (Accumulated Deficit) -$1.09B.
- 2025-11-30: Retained Earnings (Accumulated Deficit) -$1.00B.
- 2025-08-31: Retained Earnings (Accumulated Deficit) -$925.00M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-05-31 | -$1.18B 10-Q · filed 2026-07-09 |
| 2026-02-28 | -$1.09B 10-Q · filed 2026-04-08 |
| 2025-11-30 | -$1.00B 10-Q · filed 2026-07-09 |
| 2025-08-31 | -$925.00M 10-Q · filed 2025-10-09 |
| 2025-05-31 | -$838.58M 10-Q · filed 2025-07-09 |
| 2025-02-28 | -$795.12M 10-Q · filed 2025-04-08 |
| 2024-11-30 | -$738.77M 10-K · filed 2026-01-28 |
| 2024-08-31 | -$680.22M 10-Q · filed 2024-10-11 |
| 2024-05-31 | -$631.26M 10-Q · filed 2024-07-11 |
| 2024-02-29 | -$586.72M 10-Q · filed 2024-04-10 |
| 2023-11-30 | -$545.20M 10-K · filed 2025-01-28 |
| 2023-08-31 | -$503.24M 10-Q · filed 2023-10-12 |
| 2023-05-31 | -$466.26M 10-Q · filed 2023-07-13 |
| 2023-02-28 | -$441.99M 10-Q · filed 2023-04-13 |
| 2022-11-30 | -$401.25M 10-K · filed 2024-02-15 |
| 2022-08-31 | -$354.54M 10-Q · filed 2022-10-06 |
| 2022-05-31 | -$308.83M 10-Q · filed 2022-07-07 |
| 2022-02-28 | -$263.43M 10-Q · filed 2022-04-08 |
| 2021-11-30 | -$220.89M 10-K · filed 2023-02-09 |
| 2021-08-31 | -$183.19M 10-Q · filed 2021-10-14 |
| 2021-05-31 | -$154.35M 10-Q · filed 2021-07-13 |
| 2021-02-28 | -$127.97M 10-Q · filed 2021-04-13 |
| 2020-11-30 | -$103.70M 10-K · filed 2022-01-28 |
| 2020-08-31 | -$83.78M 10-Q · filed 2020-10-14 |
| 2019-11-30 | -$60.46M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |